Ctrl K
Wall Street consensus, price target range, and equity research thesis
Wall Street currently rates ABBV buy with a 12-month price target of $285 (+14.3% upside). The sections below cover the bull case, key risks, and latest earnings context for AbbVie Inc..
Analyst ratings update weekly. Get ABBV's next verdict in your inbox.
Free. No account needed. Unsubscribe any time.
Analyst Research Summary
A structured look at the bull case, the risks, and the most recent earnings execution for ABBV.
ABBV beat estimates last quarter. Below are the key reasons analysts remain constructive and the risks that could change that view.
What keeps the long thesis intact
Wall Street rates ABBV buy, giving the bull case institutional backing from 41 analysts.
What can break the setup quickly
Watch whether new negative commentary on ABBV points to these structural risks or is simply reacting to short-term price moves.
Last Quarter
Stock snapshot, live price chart, key ratios, and company profile.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ABBV stock.
ABBV has modest upside — analysts rate it "Buy" with a $285 target, implying +14.3% from today's $249.45. This is informational only — verify the data and consider your own risk tolerance before deciding.
Timing depends on your horizon, but the data signals are: consensus rating "Buy" with +14.3% upside to the $285 target.
ABBV's consensus 12-month price target is $285, set by 41 Wall Street analysts. The bull case high is $300 and the bear case low is $235. From the current price of $249.45, this implies +14.3% upside.
ABBV appears fairly valued — the $285 consensus target is roughly in line with today's $249.45 (+14.3%). It trades at a forward P/E of 17.7x. Targets range from $235 (bear) to $300 (bull), reflecting different assumptions about growth and margins.
ABBV reports next quarter. Earnings-week moves are volatile — historically, analyst targets revise upward after a beat and downward after a miss. The current consensus is "Buy" with a $285 target. Consider position sizing rather than going all-in pre-print.
Of 41 analysts covering AbbVie Inc. (ABBV): 0 Strong Buy, 29 Buy, 11 Hold, 1 Sell, 0 Strong Sell — a "Buy" consensus. The 12-month price target is $285 (range $235–$300). Bullish analysts outnumber bearish by more than 2-to-1.
1 of the 41 analysts covering ABBV rate it Sell or Strong Sell. Common concerns include valuation stretch, slowing growth, and sector-specific headwinds — see the Bull vs. Risk cards above for the specific theses on AbbVie Inc..
Financial Data & Software Notice: VCP Scanner is an educational financial research database and stock screening software platform. VCP Scanner does not generate, recommend, or package trade decisions, buy/sell signals, or personalized investment advice. Consensus ratings and price targets reflect aggregated third-party Wall Street analyst research from public SEC filings. See our Terms of Service and Privacy Policy.